Evidence map›Paper›PMID 33303704›Full record

ArticleBlood research2020

First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL/CLL patients.

Hebatallah Adel Sedky, Soha Raouf Youssef, Doaa Ahmad Gamal, Heba Fawzy Houssein, Walaa Ali Elsalakawy

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hebatallah Adel SedkyClinical Pathology Department, Internal Medicine Department, Ain Shams University, Faculty of Medicine, Cairo, Egypt.
Soha Raouf YoussefClinical Pathology Department, Internal Medicine Department, Ain Shams University, Faculty of Medicine, Cairo, Egypt.
Doaa Ahmad GamalClinical Pathology Department, Internal Medicine Department, Ain Shams University, Faculty of Medicine, Cairo, Egypt.
Heba Fawzy HousseinClinical Pathology Department, Internal Medicine Department, Ain Shams University, Faculty of Medicine, Cairo, Egypt.
Walaa Ali ElsalakawyClinical Hematology and Bone Marrow Transplant Unit, Internal Medicine Department, Ain Shams University, Faculty of Medicine, Cairo, Egypt.
Ain Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphoproliferative disorders (LPDs) are a heterogeneous group of diseases characterized by an uncontrolled production of monoclonal lymphocytes. RECAF is the receptor for alpha-fetoprotein, which is re-expressed on malignant cells, thus serving as a broad-spectrum tumor marker.

methodsThe current study is a retrospective study carried out on 200 archival bone marrow trephine biopsy specimens [60 normal control (NC), 38 pathological control (PC) and 102 lymphoproliferative diseases (LPD) specimens]. RECAF expression was assessed using immunohistochemistry.

resultsThe percentage of cells that are positive for RECAF was significantly higher in the LPD group than in the NC group (P=0.007), while there was no significant difference between non-Hodgkin lymphoma (NHL) patients and PC regarding the number of RECAF positive cells (P=0.1). RECAF showed a unique expression pattern among the different subtypes of LPD. None of the hairy cell leukemia (HCL) expressed RECAF, while the highest percentage was seen in follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) (P=0.001). Compared to routine histopathology, RECAF was more sensitive in detecting bone marrow (BM) infiltration in FL, mantle cell lymphoma (MCL), and DLBCL (P=0.01).

conclusionRECAF is significantly expressed in the BM of NHL/chronic lymphocytic leukemia (CLL) patients. RECAF shows a unique expression pattern among the different subtypes of LPD. Furthermore, RECAF may help to detect bone marrow infiltration in lymphoma cells. This may help in the diagnosis, follow-up, and targeting of LPD.

Indexed as

Chronic lymphocytic leukemiaDiffuse large B cell lymphomaFollicular lymphomaHairy cell leukemiaLymphomaRECAF

Identifiers

PMID33303704
PMCPMC7784125
OpenAlexW3111006199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.